Research programme: stem cell-based therapeutics - International Stem Cell Corporation

Drug Profile

Research programme: stem cell-based therapeutics - International Stem Cell Corporation

Alternative Names: Human parthenogenetic stem cells - International Stem Cell Corporation; Induced pluripotent stem cells - International Stem Cell Corporation; iPS cells - International Stem Cell Corporation; iPSC; Safe iPS cells - International Stem Cell Corporation

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator International Stem Cell Corporation
  • Developer International Stem Cell Corporation; University of California at San Francisco
  • Class Antirheumatics; Eye disorder therapies; Hepatoprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Osteoarthritis
  • No development reported Blindness; Crigler-Najjar syndrome
  • Discontinued Diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Blindness in USA (Intraocular, Implant)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Crigler-Najjar syndrome in USA (Implant)
  • 31 Oct 2017 International Stem Cell Corporation receives patent allowance for methods for generating HLA homozygous parthenogenetic human stem cell lines in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top